Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 460

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 460
---
ulated deficit                                                                                                                                                                                                                                 | ​ | ​ | ​            | ​ | -14,883,124 | ​ | ​ | ​ | ​    | ​ | -13,974,105 | ​ | ​ |
| Total Stockholders’ Deficit                                                                                                                                                                                                                         | ​ | ​ | ​            | ​ | -14,742,434 | ​ | ​ | ​ | ​    | ​ | -13,833,415 | ​ | ​ |
| Total Liabilities, Common Stock Subject to Possible Redemption and Stockholders’ Deficit                                                                                                                                                            | ​ | ​ | ​            | $ |   4,502,213 | ​ | ​ | ​ | ​    | $ |  15,488,270 | ​ | ​ |

(1) As of December 31, 2023, $85,084 of the $156,425 cash balance is classified as restricted cash to be used for tax payments only.

The accompanying notes are an integral part of these financial statements. F-29

TABLE OF CONTENTS

IRIS ACQUISITION CORP
STATEMENTS OF OPERATIONS

| ​                                                                                                          
 ​                                                                                                          | ​ 
 ​ | ​ 
 ​ | For the years ended December 31, 
 2023                             |   |            |   | ​ | ​ | 2022 |   |            |   | ​ 
 ​ |
|:-----------------------------------------------------------------------------------------------------------|:--|:--|:---------------------------------|:--|-----------:|:--|:--|:--|:-----|:--|-----------:|:--|:--|
| Formation and operating costs                                                                              | ​ | ​ | ​                                | $ | -2,586,211 | ​ | ​ | ​ | ​    | $ | -2,452,467 | ​ | ​ |
| Forgiveness of unrelated vendor payables                                                                   | ​ | ​ | ​                                | ​ |    275,000 | ​ | ​ | ​ | ​    | ​ |    579,989 | ​ | ​ |
| Loss from operations                                                                                       | ​ | ​ | ​                                | ​ | -2,311,211 | ​ | ​ | ​ | ​    | ​ | -1,872,478 | ​ | ​ |
| Other income (expense):                                                                                    | ​ | ​ | ​                                | ​ |          ​ | ​ | ​ | ​ | ​    | ​ |          ​ | ​ | ​ |
| Unrealized gain on change in fair value of warrant